Publications dans lesquelles il/elle collabore avec MARÍA VICTORIA CALVO HERNÁNDEZ (30)

2023

  1. Efectos adversos de la interacción triple whammy detectados en un servicio de urgencias hospitalario

    Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias, Vol. 35, Núm. 5, pp. 394-396

  2. Medication delivery errors in outpatients with percutaneous endoscopic gastrostomy: effect on tube feeding replacement

    Scientific Reports, Vol. 13, Núm. 1

2022

  1. Physiologically-based pharmacokinetic modelling and dosing evaluation of gentamicin in neonates using PhysPK

    Frontiers in Pharmacology, Vol. 13

2021

  1. Evaluation of current amikacin dosing recommendations and development of an interactive nomogram: The role of albumin

    Pharmaceutics, Vol. 13, Núm. 2, pp. 1-13

2020

  1. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 6, pp. 1165-1175

  2. Amikacin initial dosage in patients with hypoalbuminaemia: an interactive tool based on a population pharmacokinetic approach

    The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 8, pp. 2222-2231

  3. Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease

    European Journal of Pharmaceutical Sciences, Vol. 150

2019

  1. Evaluation of renal function equations to predict amikacin clearance

    Expert Review of Clinical Pharmacology, Vol. 12, Núm. 8, pp. 805-813

  2. Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases

    Annals of Clinical Biochemistry, Vol. 56, Núm. 1, pp. 28-41

2018

  1. Diseño de un modelo poblacional para la monitorización farmacocinética de infliximab en enfermedad inflamatoria intestinal

    Farmajournal, Vol. 3, Núm. 1, pp. 77-85

  2. Diseño y validación de una ecuación para la dosificación inicial de vancomicina en pacientes ancianos

    Farmajournal, Vol. 3, Núm. 1, pp. 111-119

2017

  1. Pharmacokinetics and dosing requirements of digoxin in pregnant women treated for fetal supraventricular tachycardia

    Expert Review of Clinical Pharmacology, Vol. 10, Núm. 8, pp. 911-917

2011

  1. Modification of the EMIT immunoassay for the measurement of unbound mycophenolic acid in plasma

    Clinical Biochemistry, Vol. 44, Núm. 2-3, pp. 260-263

2010

  1. Clinical repercussions of analytical interferences due to aldosterone antagonists in digoxin immunoassays: An assessment

    Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 169-176

2009

  1. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients

    Journal of Pharmacy and Pharmacology, Vol. 61, Núm. 6, pp. 759-766

2008

  1. Recomendaciones para la monitorización de antibióticos en pacientes críticos ingresados en UCI

    Enfermedades Infecciosas y Microbiologia Clinica

  2. Recommendations for antibiotic monitoring in ICU patients

    Farmacia Hospitalaria

2007

  1. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients

    Intensive Care Medicine, Vol. 33, Núm. 2, pp. 279-285

2005

  1. Time-dependent pharmacokinetics of cyclosporine (Neoral®) in de novo renal transplant patients

    Journal of Clinical Pharmacy and Therapeutics, Vol. 30, Núm. 6, pp. 549-557

2004

  1. Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates

    Journal of Antimicrobial Chemotherapy, Vol. 54, Núm. 1, pp. 193-198